Medicamen Biotech Ltd (MEDICAMEQ) — Board Meeting | 28 September 2026

Medicamen Biotech held its 33rd AGM on September 26, 2026, where shareholders approved all eight resolutions including adoption of standalone and consolidated financial statements for FY2026, declaration of final dividend, reappointment of directors Suresh Kumar Singh and Sanjay Bansal, ratification of cost auditor remuneration, and approval of material related party transactions with Shivalik Rasayan Limited and Medicamen Life Sciences Private Limited. Voting results showed overwhelming approval with 99.999% in favor for most resolutions and negligible dissent. The meeting was conducted via video conferencing and electronic voting, with 12,110 shareholders participating. No material changes were reported compared to prior periods, and no forward guidance was provided. The filing confirms routine governance outcomes without operational or financial shifts.